Articles
23 June 2009
Vol. 2 No. 5: New Drugs in Hematology, Bologna, Italy 5-7 October 2008
https://doi.org/10.4081/hmr.v2i5.725

A Phase II international, multicenter study of oral panobinostat (LBH589) in patients with refractory cutaneous T-cell lymphoma

Publisher's note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.
203
Views
202
Downloads

Authors

MG Bernengo
support@pagepress.org
F Vanaclocha
M Duvic
T Kuzel
F Kerdel
L Pinter-Brown
A Bosly
C Okada
D Breneman
PL Zinzani
J Becker
L Hughey
M Ardaiz
J Zain
L Zhang
Background Panobinostat (LBH589) is a potent pan-deacetylase inhibitor (DACi) which has demonstrated activity in patients (pts) with CTCL in a Phase I study (Prince et al., ASCO 2007).

Altmetrics

Downloads

Citations

Crossref
Scopus
Google Scholar
Europe PMC

Supporting Agencies

How to Cite



A Phase II international, multicenter study of oral panobinostat (LBH589) in patients with refractory cutaneous T-cell lymphoma. (2009). Hematology Meeting Reports (formerly Haematologica Reports), 2(5). https://doi.org/10.4081/hmr.v2i5.725